Procaps Group (Procaps Group) Momentum Rank : 0 (As of May. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Momentum Rank?

Procaps Group has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Procaps Group Momentum Rank Related Terms

Thank you for viewing the detailed overview of Procaps Group's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group (Procaps Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371